The "Asthma and Severe Asthma: Epidemiology Forecast to 2033" report has been added to ResearchAndMarkets.com's offering. The Asthma and Severe Asthma Epidemiology Report and Model provide an overview ...

Clinical studies found Dupixent effective for treating eosinophilic or oral corticosteroid ... are recognized as treatment options by the Asthma and Allergy Foundation of America (AAFA).

Exhaled Nitric Oxide and Sputum Eosinophils are Complementary Tools for Diagnosing Occupational Asthma suggests a study ...

Current treatments focus on eosinophilic asthma, neglecting non-eosinophilic types. Developments in biologic therapies for severe asthma, challenges remain in managing T-helper cell type 2 (T2)-low ...

A Potential Therapeutic Target for Steroid Resistant Asthma,” published in the December 2024 issue of Allergy and Immunology ...

An elemental diet is a medical protocol that replaces food and drinks with liquid formula for people with serious GI ...

It matched Xolair on improving symptoms in allergic asthma, while it effect on AAER was "somewhat greater". Tezepelumab's greatest potential lies in non-eosinophil severe asthma however – which ...

Increased ET-1 levels have been demonstrated in the bronchial epithelium of asthma patients ... symptoms of allergy. ECP is a marker of the activity and turnover of the eosinophil granulocyte.

pro-inflammatory cytokines that drive exacerbations in asthma symptoms. "Tezepelumab has demonstrated reductions in exacerbations irrespective of blood eosinophil counts, allergy status and ...

Anti-IL-4Rα monoclonal antibodies are among the best-selling biologics in this field. MG-K10 is an innovative long-acting anti-IL-4Rα humanizedmonoclonal antibody that simultaneously blocks the ...

China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 24 January ...